Comparing the current results to its competitors, Enanta Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2026 year on year by -21.6 %, despite the revenue increase by the most of its competitors of 6.36 %, recorded in the same quarter.
Enanta Pharmaceuticals Inc, slower than the average decrease reported by the company's competitors of -56.24 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -56.24 %
Enanta Pharmaceuticals Inc's Comment on Competition and Industry Peers
Several companies are developing antiviral treatments and prophylaxis for respiratory syncytial virus (RSV), including Ark Biosciences, Shionogi, AstraZeneca/Sanofi (BEYFORTUS®), Merck (ENFLONSIA™), and Pfizer (ABRYSVO®). In chronic spontaneous urticaria (CSU) treatment, companies developing KIT inhibitors include Celldex (barzolvolimab), Jasper (briquilimab), and Sanofi/Blueprint. The moderate-to-severe atopic dermatitis (AD) treatment landscape features biologics such as DUPIXENT® (dupilumab), ADBRY® (tralokinumab-ldrm), EBGLYSS™ (lebrikizumab-lbkz), and Janus kinase (JAK) inhibitors including RINVOQ® (upadacitinib) and CIBINQO® (abrocitinib). Oral therapies in development for AD include candidates from Evommune, Corvus, and Kymera. For SARS-CoV-2, approved oral antivirals include PAXLOVID™ and LAGEVRIO™, with Pfizer/ibuzatrelvir in Phase 3 clinical trials. In hepatitis B virus (HBV) treatment, companies with combination regimens in late-stage studies include Vir, GSK, Arbutus, and Roche. The company operates in a competitive environment alongside multiple large pharmaceutical and biotechnology firms with extensive resources and late-stage drug candidates across indications including hepatitis C virus (HCV), RSV, SARS-CoV-2, HBV, CSU, and AD.
June 11, 2025
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a biotechnology company renowned for its innovation in small molecule drugs targeting viral infections and immunological diseases, has recently secured a significant milestone. The U.S. Food and Drug Administration (FDA) has granted approval for an expanded indication for MAVYRET (glecaprevir/pibrentasvir), a pangenotypic direct-acting antiviral (DAA). This approval positions MAVYRET as the first and only eight-week treatment option for both adults and pediatric patients aged three and older with acute hepatitis C virus (HCV) infections.The expanded label underscores Enanta’s commitment to addressing the diverse needs of patients suffering from HCV. The eight-we...
Publicly Traded Peers of Enanta Pharmaceuticals Inc
Gilead Sciences Inc Share Performance
+3.65%
Over The Past 5 Days
Gilead Sciences Inc
Profile
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Enanta Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Enanta Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
